Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $180 from $150 and keeps a Buy rating on the shares. The firm’s ...

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...

We delivered strong revenue growth in 2024 and significantly advanced our industry leading neuroscience pipeline, including achievement of ...

Jan. 15, 2025 — Regular aerobic exercise could significantly reduce disease markers associated with Alzheimer's, new research has found. The findings provide new hope in the battle against this ...

Axsome Therapeutics, Inc., a biopharmaceutical company ... It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed ...

Jan. 13, 2025 — Mild cognitive impairment is linked to blood vessel dysfunction in the brain's temporal lobes -- the seat of memory -- according to a new study. The findings, seen in people with ...

including achievement of positive Phase 3 results for AXS-05 in Alzheimer’s disease agitation and for AXS-12 in narcolepsy, supporting planned regulatory filings for these indications ...

Primary progressive aphasia (PPA) may develop in people with Alzheimer’s disease. Aphasia is an impairment of speech and language comprehension which also affects the ability to read and write.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

was among the first to receive new infusions that are slowing the progression of Alzheimer’s Disease and are invigorating the Alzheimer’s Associations vision for the next decade.